Details

Autor(en) / Beteiligte

• Sugaya, Norio
• Shinjoh, Masayoshi
• Kawakami, Chiharu
• Yamaguchi, Yoshio
• Yoshida, Makoto
• Baba, Hiroaki
• Ishikawa, Mayumi
• Kono, Mio
• Sekiguchi, Shinichiro
• Kimiya, Takahisa
• Mitamura, Keiko
• Fujino, Motoko
• Komiyama, Osamu
• Yoshida, Naoko
• Tsunematsu, Kenichiro
• Narabayashi, Atsushi
• Nakata, Yuji
• Sato, Akihiro
• Taguchi, Nobuhiko
• Fujita, Hisayo
• Toki, Machiko
• Myokai, Michiko
• Ookawara, Ichiro
• Takahashi, Takao

Titel

Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan

Ist Teil von

• Euro surveillance : bulletin européen sur les maladies transmissibles, 2016-10, Vol.21 (42)

Ort / Verlag

Sweden: European Centre for Disease Prevention and Control (ECDC)

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.